

ASTRAZENECA
ONCOLOGY
EDUCATION

Invitation
Nordic - Baltic Masterclass
BRCA tumor testing

February, 28th 2017

AstraZeneca 



In co-operation with:

Estrid Høgdall, Professor, Dr. Sc., Ph.d., Head of Molecular Unit, Herlev Hospital, University of Copenhagen, AstraZeneca arranges a Nordic Baltic Master Class

Course Summary:

The course will focus on BRCA tumor testing in ovarian and breast cancer
Topics covered will focus on BRCA1 & BRCA2 mutations
Which patient's should we test?
How to test BRCA?
Who is going to prescribe the BRCA test?
How should the genetic counselling process look like?
What could become the future (somatic & germline testing)?

Date and time:

Tuesday the 28th February 2017 at 9:30 to 16:30

Meeting place:

Scandic Copenhagen, Vester Søgade 6, 1601 Copenhagen V

<https://www.scandichotels.com/hotels/denmark/copenhagen/scandic-copenhagen>

Participants:

Healthcare professionals working within oncology, pathology, genetics and biochemistry

Signing up for the course:

Before 15th February via email to mette.sorensen@astrazeneca.com

Please state country, workplace, your name and telephone number. Numbers of seats limited. Final registration will be confirmed by AstraZeneca

AstraZeneca cannot reimburse your travel costs



Program Tuesday the 28th February 2017

9:30-10:00 Coffee

Welcome and introduction

Why focus on BRCA1 and BRCA2 - How far are we?

10:00-10:15 *Estrid Høgdall, Professor, Dr. Sc., Ph.d., Head of Molecular Unit, Herlev Hospital, University of Copenhagen*

Hereditary breast and ovarian cancer - Consequences for the patient and their family

10:15-10:45 *Anne-Marie Gerdes, Professor, Ph.d., Head of Genetic Clinic, Rigshospitalet, University of Copenhagen*

Review of Danish guidelines in BRCA mutated Patients in breast cancer

10:45-11:15 *Bent Ejlersen, Prof. Ph.d., Head of DBCG, Dept. Of Oncology, Rigshospitalet, University of Copenhagen*

Norwegian germline BRCA testing up-front at diagnosis on patients with breast cancer

11:15-11:45 *Lovise Mæhle, MD, Ph.d. Head of Hereditary cancer unit, Oslo University Hospital*

Lunch 11:45 – 12:45

Review of Danish guidelines in BRCA mutated Patients in breast cancer

12:45-13:15 *Claus Høgdall, Professor Dr. Sc., Gynaecologic Clinic, Rigshospitalet, University of Copenhagen*

Why do we need tumor testing in ovarian cancer and who should be tested

13:15-13:45 *Mansoor Mirza, Chief Oncologist, Dept. of Oncology, Rigshospitalet, University of Copenhagen*

KIU – Women with reproductive cancers – Patient Association perspectives

13:45-14:15 *Birthe Lemley, President of KIU (Kræft I Underlivet)*

Coffee 14:15 – 14:30

How do we test in blood? What are the technical issues?

14:30-15:00 *Mads Thomassen, Associate Professor, Molecular biologist, Ph.d., Human Genetics, Department of Clinical Research, Odense University Hospital*

How do we test in tissue? What are the technical issues?

15:00-15:30 *Tim Svenstrup Poulsen, Molecular Biologist, Molecular Unit, Department of Pathology, Herlev Hospital, University of Copenhagen*

Classification of variants and implications for testing tumor tissue for germline mutations

15:30-16:00 *Thomas Hansen Head Biochemist, Ph.d., Center of Genomic Medicine, Rigshospitalet, University of Copenhagen*

Wrap-up and future demands for testing

16:00-16:30 *Estrid Høgdall, Professor, Dr., Sc., Ph.d., Head of Molecular Unit, Herlev Hospital*

Yours sincerely

Estrid Høgdall

Professor, Dr., Sc., Ph.d.
Head of Molecular Unit
Herlev Hospital

Mette Sørensen

Strategic Account Manager
AstraZeneca A/S
Nordic-Baltic MC

Per Barfod

Nordic Diagnostic Manager
AstraZeneca A/S
Nordic-Baltic MC

Ulla Jensen

National Oncology Lead DK
AstraZeneca A/S
Nordic-Baltic MC

Det er med AstraZenecas invitation og den relaterede økonomiske støtte ikke intentionen at fremkalde eller begunstige ordination af AstraZeneca lægemidler eller enhver anden uretmæssig handling som begunstiger AstraZeneca. Hvis du deltager i foranstaltninger eller afgørelser, der berører et AstraZeneca produkt eller brug (f.eks. registrering af et lægemiddel eller tilskud, udbud) inden for en rimelig frist efter at være blevet valgt som deltager / delegeret, bør du overveje ikke at deltage i disse foranstaltninger eller afgørelser, for at undgå enhver opfattelse af utilbørlig indflydelse.

Iflg. Reklamebekendtgørelsen må kun sundhedspersoner deltage i AstraZenecas efteruddannelsesarrangementer. Ved sundhedspersoner forstås læger, tandlæger, dyrlæger, farmaceuter, sygeplejersker, veterinærsygeplejersker, farmakonomer, jordemødre, bioanalytikere, kliniske diætister, radiografer, social- og sundhedsassistenter og studerende inden for disse fag.

Når du tilmelder dig dette møde, indsamler AstraZeneca dine personoplysninger (fx navn, e-mail). Formålet med indsamlingen er at administrere og bekræfte din deltagelse i mødet. AstraZeneca opbevarer dine oplysninger i en periode på 6 måneder fra den dato, hvor mødet finder sted. Ved at kontakte os skriftligt, kan du anmode om kopi af de oplysninger, som AstraZeneca har om dig, og/eller anmode om korrektion af dine oplysninger. Ved at sende os dine oplysninger, accepterer du behandlingen af dine personoplysninger som beskrevet.

Arrangementet vil blive anmeldt til Etisk Nævn for Lægemiddelindustrien (ENLI), inden arrangementets afholdelse, og arrangementet er i sin eksisterende form og indhold forhåndsgodkendt af ENLI.

ATLAS APPROVAL ID Number 1025907,011

AstraZeneca A/S, Nordic-Baltic MC, Arne Jacobsens Allé 13, DK-2300 Copenhagen S. www.connectinhealth.dk

